Shire buys repurposed Pfizer/Sanofi drugs through $260m Lumena acquisition
This article was originally published in Scrip
Shire has acquired rare disease-focused Lumena Pharmaceuticals of San Diego for $260m in cash. Lumena is developing repurposed cholesterol-lowering drugs that it licensed from Pfizer and Sanofi to treat cholestatic liver diseases. A further payment for the biotech's cash on closing and milestone payments related to ongoing clinical trials are also included in the deal.
You may also be interested in...
The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.
With $120m in Series A funding, the new company headed by former Lumena execs will advance maralixibat into Phase III in Alagille syndrome and progressive familial intrahepatic cholestasis. Shire acquired Lumena for $260m in 2014, but lost interest in the drug.
Women in leadership roles has become a much discussed issue for the biopharma industry, but less attention seems to be focused on racial diversity. Scrip's panel talks about challenges and opportunities, and offers advice for next generation employees.